Results 1 to 10 of about 75,961 (168)

Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage III epithelial ovarian cancer: Follow‐up of long‐term survival [PDF]

Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 5, Page 988-997, May 2025.
This study provides further evidence supporting the long‐term efficacy of HIPEC for the primary treatment of advanced ovarian cancer. The PCS‐HIPEC approach achieved superior survival outcomes when optimal cytoreduction was possible. Abstract Introduction The survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) has been well defined at
Ziying Lei, Yue Wang, Runya Fang, Ke Wang, Jun Tian, Yangxiao Chen, Yingsi Wang, Jiali Luo, Jinfu He, Binghui Ding, Xianzi Yang, Li Wang, Shuzhong Cui, Hongsheng Tang, for the Chinese Peritoneal Oncology Study group (Gynecologic Oncology Study group)   +14 more
wiley   +2 more sources

Worldwide barriers of optimal surgical care provision in advanced ovarian cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Ovarian cancer (OC) remains one of the most challenging gynecological malignancies to cure, despite recent advances in treatment. Disparities in the diagnosis, management, and survival of OC exist worldwide and addressing them remains an ongoing challenge.
Shriya Varghese, Myong Cheol Lim, Robert Armbrust, Rene Pareja, Christina Fotopoulou   +4 more
wiley   +1 more source

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease.
Pawel Kordowitzki, Britta Lange, Kevin M. Elias, Marcia C. Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli   +6 more
wiley   +1 more source

Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta‐Analysis

Cancer Innovation, Volume 4, Issue 4, August 2025.
Our systematic review and meta‐analysis provide a comprehensive overview of the diagnostic value of 18F‐FDG PET/CT for identifying recurrence or metastasis in postoperative ovarian cancer patients with elevated serum CA125 levels. The pooled sensitivity, specificity, and accuracy were 94%, 83%, and 94%, respectively. These findings suggest that 18F‐FDG
Zuowei Zou, Luhua Xia, Saikang Tang, Lin Lin, Quanyang Wu, Donghui Hou, Shijun Zhao   +6 more
wiley   +1 more source

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, Volume 19, Issue 5, Page 1436-1451, May 2025.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source

The Role of CA‐125 in the Management of Ovarian Cancer: A Systematic Review

Cancer Reports, Volume 8, Issue 3, March 2025.
ABSTRACT Background Ovarian cancer is frequently occurring and fatal for women. CA‐125 is important in the screening, diagnosis, and treatment of ovarian cancer. This review study was conducted to explore the influence of CA‐125 in addressing ovarian cancer.
Zohre Momenimovahed, Afrooz Mazidimoradi, Leila Allahqoli, Hamid Salehiniya   +3 more
wiley   +1 more source

Tumor Cell‐Expressed Herpesvirus Entry Mediator Regulates Proliferation and Adaptive Immunity in Ovarian Cancer

Immunity, Inflammation and Disease, Volume 13, Issue 3, March 2025.
(1) Tumor cell‐expressed herpesvirus entry mediator (HVEM) was found to promote ovarian cancer (OvCa) cell proliferation by partly activating XBP1s‐cMyc signaling. (2) Tumor cell‐expressed HVEM specifically affected the effects of adaptive immunity and contributed to OvCa progression in mice.
Yun Lu, Yijun Zhang, Wenxuan Li, Haonan Jiang, Jiapo Wang, Xiaoqing Guo   +5 more
wiley   +1 more source

Liver Metastasis in Cancer: Molecular Mechanisms and Management

MedComm, Volume 6, Issue 3, March 2025.
This review focuses on the molecular mechanisms and clinical management of tumor liver metastasis. Liver metastasis is a primary manifestation of the aggressive dissemination of several extrahepatic tumors. Many risk factors, such as individual genetic background, liver diseases, diet, trauma, and medication, may accelerate this process.
Wenchao Xu, Jia Xu, Jianzhou Liu, Nanzhou Wang, Li Zhou, Junchao Guo   +5 more
wiley   +1 more source

Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid morphology on ultrasound

Ultrasound in Obstetrics &Gynecology, Volume 65, Issue 3, Page 353-363, March 2025.
ABSTRACT Objective The primary aim was to identify radiomics ultrasound features that can distinguish between benign and malignant adnexal masses with solid ultrasound morphology, and between primary malignant (including borderline and primary invasive) and metastatic solid ovarian masses, and to develop ultrasound‐based machine learning models that ...
F. Moro, M. Vagni, H. E. Tran, F. Bernardini, F. Mascilini, F. Ciccarone, C. Nero, D. Giannarelli, L. Boldrini, A. Fagotti, G. Scambia, L. Valentin, A. C. Testa   +12 more
wiley   +1 more source

Malignant Cells Beyond the Tumor Core: The Non‐Negligible Factor to Overcome the Refractory of Glioblastoma

CNS Neuroscience &Therapeutics, Volume 31, Issue 3, March 2025.
Located beyond the tumor core, questiona cells (Q cells) exhibit high invasiveness, metabolic adaptations, and drug resistance, driving tumor recurrence despite aggressive treatment. Their physical properties, such as low solid stress and soft tissue stiffness, further enhance their migratory and invasive capabilities. Advanced imaging techniques (e.g.,
Yuyang Zhou, Qilin He, Guanglong Huang, Pei Ouyang, Hai Wang, Jiapeng Deng, Pengyu Chen, Xuan Liang, Zhisheng Hong, Xian Zhang, Songtao Qi, Yaomin Li   +11 more
wiley   +1 more source